NCT04034446View on ClinicalTrials.gov

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 30, 2019

Primary Completion Date

July 21, 2020

Study Completion Date

December 1, 2020

Conditions
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

CD19-CD22 CAR-T cells

0.5 to 3.0 x 106 autologous CD19-CD22 CAR-T cells per kg body weight, with a maximum dose of 4 x 108 autologous CD19-CD22 CAR-T cells via intravenous infusion.

Trial Locations (1)

300020

Institute of Hematology & Blood Diseases Hospital, Tianjin

Sponsors
All Listed Sponsors
collaborator

Juventas Cell Therapy Ltd.

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER